Durvalumab with Gemcitabine and Oxaliplatin in Advanced Biliary Tract Cancer
Authors:
- Makenna A. SmackMSMakenna A. Smack
- Jane E. RogersJRJane E. Rogers
- Lianchun XiaoLXLianchun Xiao
- Sunyoung S. LeeSLSunyoung S. Lee
- Shubham PantSPShubham Pant
- Ahmed O. KasebAKAhmed O. Kaseb
- Brandon G. SmagloBSBrandon G. Smaglo
- Victoria HigbieVHVictoria Higbie
- Zishou Ian HuZHZishou Ian Hu
- Amy AnAAAmy An
- Milind JavleMJMilind Javle
Open Access
Abstract
Background: Gemcitabine, cisplatin and durvalumab or pembrolizumab are standard first-line treatments for advanced or metastatic biliary tract cancer (BTC). Older patients with BTC may be frail or have contraindications to cisplatin. At our institution, oxaliplatin has been used as an alternative to cisplatin. Methods: In this evaluation, we report the safety and efficacy of gemcitabine with oxaliplatin and durvalumab as a first-line treatment of BTC. The primary objective was overall survival (OS). Secondary objectives included time to progression (TTP), disease control rate (DCR), and the incidence of treatment-related toxicities. Results: Twenty-nine patients were included. The majority were Caucasian (97%) and had an Eastern Cooperative Oncology Group (ECOG) performance status of 0–1 (97%). Median age was 72 years old. Sixty-six percent had intrahepatic cholangiocarcinoma. Baseline renal insufficiency and/or hearing impairment were the most common reasons for cisplatin contraindication. Median follow-up was 20.6 months. Treatment cycles were every 28 days with durvalumab (1500 mg) given on day 1 and gemcitabine (range 600 mg/m2–1000 mg/m2) plus oxaliplatin (median dose 70 mg/m2) given on days 1 and 15. Median OS was 15.7 months (95% CI: 6.9-NA), median TTP was 6.7 months (95% CI 3.88-NA), and DCR was 76%. Median time on treatment was 3.15 months. Twelve patients (41%) required a dose adjustment, with myelosuppression as the most common toxicity. Conclusions: Oxaliplatin, in combination with durvalumab and gemcitabine, is a suitable platinum substitute for advanced BTC patients when cisplatin is contraindicated. Our analysis showed similar efficacy and no new safety concerns. Given the small sample size, our analysis is hypothesis-generating and calls for a larger prospective analysis.Keywords
Funding Information
- Marther fund
- Mark Mobius fund
This publication has 21 references indexed in Scilit:
- Nationwide Response to Carboplatin and Cisplatin Shortages in Lung CancerJAMA Oncology, 2025
- 45P Durvalumab (D) plus gemcitabine-based (gem-based) chemotherapy as first-line therapy for Chinese patients (pts) with advanced biliary tract cancers (aBTC): A phase IIIb, single arm, open-label, multi-center study (TopDouble)Annals of Oncology, 2024
- Molecular profiling in cholangiocarcinoma: A practical guide to next-generation sequencingCancer Treatment Reviews, 2023
- Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trialThe Lancet, 2023
- 68O Impact of mutation status on efficacy outcomes in TOPAZ-1: A phase III study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (+GC) in advanced biliary tract cancer (BTC)Annals of Oncology, 2022
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerNew England Journal of Medicine, 2012
- Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract CancerNew England Journal of Medicine, 2010
- Gemcitabine and oxaliplatin in patients with unresectable biliary cancer including gall bladder cancer: a Korean Cancer Study Group phase II trialCancer Chemotherapy and Pharmacology, 2009
- A phase II study of gemcitabine in combination with oxaliplatin as first-line chemotherapy in patients with inoperable biliary tract cancerCancer Chemotherapy and Pharmacology, 2009
- Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II studyBritish Journal of Cancer, 2008